The University of Southampton
University of Southampton Institutional Repository

Definition of response in randomized controlled trials of medications for attention-deficit/hyperactivity disorder across the lifespan: a systematic review

Definition of response in randomized controlled trials of medications for attention-deficit/hyperactivity disorder across the lifespan: a systematic review
Definition of response in randomized controlled trials of medications for attention-deficit/hyperactivity disorder across the lifespan: a systematic review

Objectives: Randomized controlled trials (RCTs) are the gold standard for evaluating medication efficacy. The absence of a universal definition of treatment response, based on the degree of symptom improvement measured by standardized rating scales in the field of attention-deficit/hyperactivity disorder (ADHD), makes it difficult to compare treatment outcomes across RCTs. Here, we aimed to assess to what extent and how “treatment response” is defined across RCTs of ADHD medications. Methods: We identified eligible RCTs via the MED-ADHD database (https://med-adhd.org/), which compiles RCTs evaluating the efficacy and safety of pharmacological treatments for children, adolescents, and adults with ADHD, based on a comprehensive search in multiple electronic databases, including PubMed, BIOSIS Previews, CINAHL, the Cochrane Central Registry of Controlled Trials, and EMBASE, up to 17 January 2025, alongside additional unpublished information gathered from manufacturers/study authors. Results: Out of 167 RCTs in MED-ADHD, 88 defined treatment response based on reductions in ADHD core symptom severity using rating scale scores. The most frequently used threshold was a ≥30% reduction in attention-deficit/hyperactivity disorder (ADHD-RS) scores, with other RCTs using ≥25%, ≥40%, or ≥50%. In addition, RCTs applied similar cutoff values to alternative scales, including Conner’s Adult ADHD Rating Scale, SNAP-IV, Adult ADHD Investigator Rating Scale, and Wender-Reimherr Adult Attention Deficit Disorder Scale. However, 79 studies did not specify any response threshold. Conclusion: Our review underscores and quantitatively defines the inconsistency in the definition of treatment response across ADHD medication trials, highlighting the urgent need for the field to reach a consensus on the use of a standardized definition of “treatment response” for each rating scale, based on the percentage reduction in ADHD core symptom severity.

attention-deficit/hyperactivity disorder (ADHD), pharmacological treatment, randomized controlled trials (RCTs), standardized definition, treatment response
1044-5463
321-325
Roy, Sulagna
e19ccb41-6850-40b7-8da4-7952b1c8cf2d
Colacicco, Giuseppe
2b4e28b9-8f21-49c0-b481-62c5dfab886b
Frigeri, Giorgia
a2ebb5c2-2010-475c-aa1b-81a8627b9b09
Tarantino, Fabio
a14d04b9-b967-4790-aaad-df2fa1a1c3b3
Matera, Emilia
abf9c93d-f5c9-4d9e-80f8-3e255b5b4728
Petruzzelli, Maria giuseppina
d96b60fc-f1b9-4bd1-9cd6-9ac133e0b89f
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Roy, Sulagna
e19ccb41-6850-40b7-8da4-7952b1c8cf2d
Colacicco, Giuseppe
2b4e28b9-8f21-49c0-b481-62c5dfab886b
Frigeri, Giorgia
a2ebb5c2-2010-475c-aa1b-81a8627b9b09
Tarantino, Fabio
a14d04b9-b967-4790-aaad-df2fa1a1c3b3
Matera, Emilia
abf9c93d-f5c9-4d9e-80f8-3e255b5b4728
Petruzzelli, Maria giuseppina
d96b60fc-f1b9-4bd1-9cd6-9ac133e0b89f
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb

Roy, Sulagna, Colacicco, Giuseppe, Frigeri, Giorgia, Tarantino, Fabio, Matera, Emilia, Petruzzelli, Maria giuseppina and Cortese, Samuele (2025) Definition of response in randomized controlled trials of medications for attention-deficit/hyperactivity disorder across the lifespan: a systematic review. Journal of Child and Adolescent Psychopharmacology, 35 (6), 321-325. (doi:10.1089/cap.2025.0029).

Record type: Article

Abstract

Objectives: Randomized controlled trials (RCTs) are the gold standard for evaluating medication efficacy. The absence of a universal definition of treatment response, based on the degree of symptom improvement measured by standardized rating scales in the field of attention-deficit/hyperactivity disorder (ADHD), makes it difficult to compare treatment outcomes across RCTs. Here, we aimed to assess to what extent and how “treatment response” is defined across RCTs of ADHD medications. Methods: We identified eligible RCTs via the MED-ADHD database (https://med-adhd.org/), which compiles RCTs evaluating the efficacy and safety of pharmacological treatments for children, adolescents, and adults with ADHD, based on a comprehensive search in multiple electronic databases, including PubMed, BIOSIS Previews, CINAHL, the Cochrane Central Registry of Controlled Trials, and EMBASE, up to 17 January 2025, alongside additional unpublished information gathered from manufacturers/study authors. Results: Out of 167 RCTs in MED-ADHD, 88 defined treatment response based on reductions in ADHD core symptom severity using rating scale scores. The most frequently used threshold was a ≥30% reduction in attention-deficit/hyperactivity disorder (ADHD-RS) scores, with other RCTs using ≥25%, ≥40%, or ≥50%. In addition, RCTs applied similar cutoff values to alternative scales, including Conner’s Adult ADHD Rating Scale, SNAP-IV, Adult ADHD Investigator Rating Scale, and Wender-Reimherr Adult Attention Deficit Disorder Scale. However, 79 studies did not specify any response threshold. Conclusion: Our review underscores and quantitatively defines the inconsistency in the definition of treatment response across ADHD medication trials, highlighting the urgent need for the field to reach a consensus on the use of a standardized definition of “treatment response” for each rating scale, based on the percentage reduction in ADHD core symptom severity.

Text
RoyManuscriptCleanVersionV1.1 - Accepted Manuscript
Download (100kB)

More information

e-pub ahead of print date: 14 May 2025
Published date: 1 August 2025
Keywords: attention-deficit/hyperactivity disorder (ADHD), pharmacological treatment, randomized controlled trials (RCTs), standardized definition, treatment response

Identifiers

Local EPrints ID: 503114
URI: http://eprints.soton.ac.uk/id/eprint/503114
ISSN: 1044-5463
PURE UUID: f1776ac3-750d-4332-bb71-0f0d602512e8
ORCID for Sulagna Roy: ORCID iD orcid.org/0009-0005-6824-7266
ORCID for Samuele Cortese: ORCID iD orcid.org/0000-0001-5877-8075

Catalogue record

Date deposited: 22 Jul 2025 16:30
Last modified: 13 Sep 2025 02:34

Export record

Altmetrics

Contributors

Author: Sulagna Roy ORCID iD
Author: Giuseppe Colacicco
Author: Giorgia Frigeri
Author: Fabio Tarantino
Author: Emilia Matera
Author: Maria giuseppina Petruzzelli
Author: Samuele Cortese ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×